FDA-approved carbonic anhydrase inhibitors reduce Amyloid beta pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness
Elisa Canepa, Rebecca Maria Parodi‐Rullán, Rafael Vázquez‐Torres, Begona Gamallo‐Lana, Roberto A Guzman‐Hernandez, Nicole L Lemon, Federica Angiulli, Ludovic Debure, Marc Antoniu Ilies, Leif Østergaard, Thomas Wısnıewskı, Eugenio Gutiérrez‐Jiménez, Adam C. Mar, Silvia Fossati
This study tests FDA-approved carbonic anhydrase inhibitors in a transgenic AD model, finding they reduce amyloid beta pathology and improve cognition by enhancing cerebrovascular health and glial function.
Alzheimer s & Dementia · Apr 26, 2023Peer-reviewedNeuroscience